Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alisertib plus Paclitaxel in SCLC
NCT02038647Phase 2Completed
- Sponsor
- Millennium Pharmaceuticals
- Start
- May 2014
- Primary completion
- Jan 2016
- Modality
- Small Molecules
- Countries
- 10
01
Overview
A Phase 2 trial of alisertib in small cell lung cancer (SCLC), sponsored by Millennium Pharmaceuticals. Started May 2014; status: completed.
02
Drugs
alisertib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT02038647.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02038647.